Primecap Management Co. CA Reduces Bristol Myers Squibb Stake

Institutional investor sells over 850,000 shares of pharmaceutical company

Feb. 26, 2026 at 12:34pm

Got story updates? Submit your updates here. ›

Primecap Management Co. CA, a major institutional investor, reduced its stake in Bristol Myers Squibb Company by 3.7% during the third quarter, selling 850,330 shares of the biopharmaceutical company's stock. Primecap Management now owns approximately 1.09% of Bristol Myers Squibb, worth over $996 million as of its most recent filing.

Why it matters

This transaction by a prominent institutional investor provides insight into the market's sentiment towards Bristol Myers Squibb. As a large shareholder, Primecap Management's decision to trim its position could signal broader concerns or a shift in strategy regarding the pharmaceutical company's outlook and performance.

The details

According to the filing, Primecap Management Co. CA now owns 22,094,320 shares of Bristol Myers Squibb, down from 22,944,650 shares held previously. The firm cited the 3.7% reduction in its position during the third quarter. Bristol Myers Squibb's stock has seen significant volatility in recent months, with the share price ranging from a low of $42.52 to a high of $63.33 over the past year.

  • Primecap Management Co. CA filed its most recent disclosure with the SEC in the third quarter of 2026.

The players

Primecap Management Co. CA

A prominent institutional investment management firm that owns a significant stake in Bristol Myers Squibb.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Primecap Management's decision to reduce its position in Bristol Myers Squibb suggests potential uncertainty or caution around the pharmaceutical company's near-term prospects, even as it maintains a sizable investment. This transaction highlights the importance of monitoring the moves of major institutional investors when assessing the outlook for individual stocks.